Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2023-12-13 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于环泊酚注射液全部适应症被纳入国家医保目录的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the inclusion of a pharmaceutical product (环泊酚注射液) into the national medical insurance catalog (国家医保目录). It provides details about the product, its approved indications, and the effective period of the insurance agreement. There is no financial data, no mention of annual or quarterly reports, no discussion of management changes, no voting results, and no legal proceedings. The document is a regulatory announcement informing investors about a significant business development related to product reimbursement status. It is short (910 characters) and does not contain financial statements or detailed analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-12-13 Chinese
第五届监事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding the approval of the lifting of restrictions on a stock incentive plan. It includes voting results and compliance statements but does not contain financial statements or detailed financial data. The document is short (874 characters) and is an official announcement of a board decision rather than a full report or financial filing. It relates to management decisions but specifically from the Supervisory Board about stock incentive plans, which fits best under Board/Management Information (MANG).
2023-12-12 Chinese
第五届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by the company 海思科医药集团股份有限公司. It details the approval of a proposal related to the company's 2021 restricted stock incentive plan and the voting results. The document is short (788 characters) and primarily reports on a board decision rather than providing detailed financial data or a full report. It is not an annual report, audit report, or earnings release. It is also not a regulatory filing or certification. The content fits best under Board/Management Information (MANG) as it announces a board resolution and related management decisions.
2023-12-12 Chinese
关于2021年限制性股票激励计划第二个解除限售期解除限售条件成就的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the achievement of conditions for the second release period of a 2021 restricted stock incentive plan. It details the approval procedures, performance conditions, and the number of shares eligible for release. It includes board and supervisory committee opinions, legal opinions, and specific details about the stock incentive plan and its participants. The document is not a full annual or interim report, nor is it a financial statement or earnings release. It is a formal announcement related to a stock incentive plan and the unlocking of restricted shares, which fits the category of a Regulatory Filing (RNS) as it does not fall under more specific categories like Director's Dealing or Share Issue/Capital Change, since it is about the unlocking of restricted stock under an incentive plan rather than new share issuance or insider trading. The document length and detail confirm it is not a brief announcement but a full disclosure of the unlocking event and related approvals.
2023-12-12 Chinese
北京市中伦（深圳）律师事务所关于海思科医药集团股份有限公司2021年限制性股票激励计划第二个解除限售期解除限售条件成就相关事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the achievement of conditions for the second release period of a 2021 restricted stock incentive plan of a company. It discusses legal compliance, approvals, and authorizations related to the stock incentive plan, referencing company reports and regulatory requirements. It does not contain financial statements or detailed financial performance data itself, but rather legal validation of a corporate action related to stock incentives. This type of document is not an annual report, audit report, earnings release, or management report. It is a legal opinion related to a corporate governance matter concerning stock incentives. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory or compliance documents that do not fit other specific categories.
2023-12-12 Chinese
独立董事对相关事项发表的独立意见
Governance Information Classification · 95% confidence The document is an independent director's opinion on the lifting of restrictions on restricted stock under a stock incentive plan. It references compliance with stock incentive management rules and company articles, and confirms the legality and validity of the stock unlocking. The document is a formal opinion related to a specific corporate governance matter concerning stock incentives, not a full financial report or earnings release. It is not a report publication announcement or a certification letter but a governance-related statement. Therefore, it fits best under Governance Information (CGR), which covers reports detailing internal rules, board structure, and governance practices.
2023-12-12 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.